{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:49Z","timestamp":1792791469779,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67945-3","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:02:31Z","timestamp":1727686951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Nassim","family":"Anjidani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Shahpari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Kafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saghar","family":"Barati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"67945_CR1","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","volume":"39","author":"L Li","year":"2021","unstructured":"Li, L. et al. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine 39, 5940\u20135953 (2021).","journal-title":"Vaccine"},{"issue":"23","key":"67945_CR2","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","volume":"40","author":"L Li","year":"2022","unstructured":"Li, L. et al. Covax-19\/Spikogen vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine 40(23), 3182\u20133192 (2022).","journal-title":"Vaccine"},{"issue":"48","key":"67945_CR3","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.1016\/j.vaccine.2023.10.018","volume":"41","author":"Y Honda-Okubo","year":"2023","unstructured":"Honda-Okubo, Y. et al. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants. Vaccine 41(48), 7116\u20137128 (2023).","journal-title":"Vaccine"},{"issue":"32","key":"67945_CR4","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1016\/j.vaccine.2023.06.063","volume":"41","author":"Y Honda-Okubo","year":"2023","unstructured":"Honda-Okubo, Y. et al. An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge. Vaccine 41(32), 4710\u20134718 (2023).","journal-title":"Vaccine"},{"key":"67945_CR5","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","volume":"28","author":"P Tabarsi","year":"2022","unstructured":"Tabarsi, P. et al. Safety and immunogenicity of SpikoGen, an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: A phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clin. Microbiol. Infect. 28, 1263\u20131271 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"67945_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","volume":"29","author":"P Tabarsi","year":"2022","unstructured":"Tabarsi, P. et al. Evaluating the efficacy and safety of SpikoGen, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: A phase 3 randomized placebo-controlled trial. Clin. Microbiol. Infect. 29, 215\u2013220 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"67945_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/imm.13540","volume":"167","author":"P Tabarsi","year":"2022","unstructured":"Tabarsi, P. et al. Immunogenicity and safety of SpikoGen, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trial. Immunology 167, 340\u2013353 (2022).","journal-title":"Immunology"},{"key":"67945_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111436","volume":"127","author":"P Tabarsi","year":"2023","unstructured":"Tabarsi, P. et al. Comparative immunogenicity and safety of SpikoGen, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: An immuno-bridging clinical trial. Int. Immunopharmacol. 127, 111436 (2023).","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"67945_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab575","volume":"9","author":"SA Coggins","year":"2022","unstructured":"Coggins, S. A. et al. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. Open Forum Infect. Dis. 9(1), ofab575 (2022).","journal-title":"Open Forum Infect. Dis."},{"issue":"12","key":"67945_CR10","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1001\/jamainternmed.2021.4580","volume":"181","author":"AK Debes","year":"2021","unstructured":"Debes, A. K. et al. Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers. JAMA Intern. Med. 181(12), 1660\u20131662 (2021).","journal-title":"JAMA Intern. Med."},{"issue":"10","key":"67945_CR11","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3390\/vaccines10101608","volume":"10","author":"S Bauernfeind","year":"2022","unstructured":"Bauernfeind, S. et al. Association between adverse reactions and humoral immune response no longer detectable after BNT162b2 booster vaccination. Vaccines (Basel) 10(10), 1608 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"67945_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00084-18","volume":"32","author":"P Zimmermann","year":"2019","unstructured":"Zimmermann, P. & Curtis, N. Factors that influence the immune response to vaccination. Clin. Microbiol. Rev. 32(2), e00084-18 (2019).","journal-title":"Clin. Microbiol. Rev."},{"key":"67945_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106700","volume":"115","author":"A Jensen","year":"2022","unstructured":"Jensen, A. et al. COVID-19 vaccines: Considering sex differences in efficacy and safety. Contemp. Clin. Trials 115, 106700 (2022).","journal-title":"Contemp. Clin. Trials"},{"issue":"2","key":"67945_CR14","first-page":"198","volume":"52","author":"A Ruggieri","year":"2016","unstructured":"Ruggieri, A. et al. The influence of sex and gender on immunity, infection and vaccination. Ann. Ist. Super Sanita 52(2), 198\u2013204 (2016).","journal-title":"Ann. Ist. Super Sanita"},{"issue":"6\u20137","key":"67945_CR15","doi-asserted-by":"publisher","first-page":"A479","DOI":"10.1016\/j.autrev.2011.11.022","volume":"11","author":"S Oertelt-Prigione","year":"2012","unstructured":"Oertelt-Prigione, S. The influence of sex and gender on the immune response. Autoimmun. Rev. 11(6\u20137), A479\u2013A485 (2012).","journal-title":"Autoimmun. Rev."},{"issue":"7","key":"67945_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132003","volume":"10","author":"L Li","year":"2015","unstructured":"Li, L. et al. Delta inulin adjuvant enhances plasmablast generation, expression of activation-induced cytidine deaminase and B-cell affinity maturation in human subjects receiving seasonal influenza vaccine. PLoS\u00a0One 10(7), e0132003 (2015).","journal-title":"PLoS\u00a0One"},{"key":"67945_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fgwh.2021.761511","volume":"2","author":"A Vassallo","year":"2021","unstructured":"Vassallo, A. et al. Sex and gender in COVID-19 vaccine research: Substantial evidence gaps remain. Front. Glob. Womens Health 2, 761511 (2021).","journal-title":"Front. Glob. Womens Health"},{"issue":"1","key":"67945_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12879-022-07175-y","volume":"22","author":"R Urakawa","year":"2022","unstructured":"Urakawa, R. et al. Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: A cross-sectional study. BMC Infect. Dis. 22(1), 179 (2022).","journal-title":"BMC Infect. Dis."},{"issue":"3","key":"67945_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/vaccines10030451","volume":"10","author":"R Koike","year":"2022","unstructured":"Koike, R. et al. Systemic adverse effects induced by the BNT162b2 vaccine are associated with higher antibody titers from 3 to 6 months after vaccination. Vaccines (Basel) 10(3), 451 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"67945_CR20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/vaccines10020233","volume":"10","author":"MS Green","year":"2022","unstructured":"Green, M. S. et al. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel) 10(2), 233 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"67945_CR21","first-page":"301","volume":"46","author":"D Guerra-Est\u00e9vez","year":"2022","unstructured":"Guerra-Est\u00e9vez, D. et al. Self-reported adverse events within the seven days following the Spikevax\u00ae (Moderna) vaccination. Farm. Hosp. 46(5), 301\u2013307 (2022).","journal-title":"Farm. Hosp."},{"issue":"7","key":"67945_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3390\/vaccines10071047","volume":"10","author":"E Ortiz-Prado","year":"2022","unstructured":"Ortiz-Prado, E. et al. A comparative analysis of a self-reported adverse events analysis after receiving one of the available SARS-CoV-2 vaccine schemes in Ecuador. Vaccines (Basel) 10(7), 1047 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"67945_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/genes11121447","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu, T. et al. Transcriptional differences for COVID-19 disease map genes between males and females indicate a different basal immunophenotype relevant to the disease. Genes (Basel) 11(12), 1447 (2020).","journal-title":"Genes (Basel)"},{"key":"67945_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720952","volume":"12","author":"H Jacobsen","year":"2021","unstructured":"Jacobsen, H. & Klein, S. L. Sex differences in immunity to viral infections. Front. Immunol. 12, 720952 (2021).","journal-title":"Front. Immunol."},{"issue":"2","key":"67945_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cellimm.2015.02.004","volume":"294","author":"A Trigunaite","year":"2015","unstructured":"Trigunaite, A., Dimo, J. & J\u00f8rgensen, T. N. Suppressive effects of androgens on the immune system. Cell Immunol. 294(2), 87\u201394 (2015).","journal-title":"Cell Immunol."},{"issue":"12","key":"67945_CR26","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.tim.2020.10.002","volume":"28","author":"RL Ursin","year":"2020","unstructured":"Ursin, R. L., Shapiro, J. R. & Klein, S. L. Sex-biased immune responses following SARS-CoV-2 infection. Trends Microbiol. 28(12), 952\u2013954 (2020).","journal-title":"Trends Microbiol."},{"issue":"38","key":"67945_CR27","doi-asserted-by":"publisher","first-page":"23751","DOI":"10.1073\/pnas.1915075117","volume":"117","author":"E Mackey","year":"2020","unstructured":"Mackey, E. et al. Perinatal androgens organize sex differences in mast cells and attenuate anaphylaxis severity into adulthood. Proc. Natl. Acad. Sci. USA 117(38), 23751\u201323761 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"67945_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2018","unstructured":"Nikolich-\u017dugich, J. The twilight of immunity: Emerging concepts in aging of the immune system. Nat. Immunol. 19(1), 10\u201319 (2018).","journal-title":"Nat. Immunol."},{"issue":"8","key":"67945_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3390\/vaccines10081220","volume":"10","author":"I Levy","year":"2022","unstructured":"Levy, I. et al. Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine. Vaccines (Basel) 10(8), 1220 (2022).","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"67945_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269917","volume":"17","author":"Y Kobashi","year":"2022","unstructured":"Kobashi, Y. et al. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLoS\u00a0One 17(6), e0269917 (2022).","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"67945_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00915-21","volume":"7","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. Correlation of immunogenicity and reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 vaccines. mSphere 7(2), e0091521 (2022).","journal-title":"mSphere"},{"issue":"9","key":"67945_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257668","volume":"16","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi, M. et al. Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS\u00a0One 16(9), e0257668 (2021).","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"67945_CR33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3904\/kjim.2021.210","volume":"36","author":"YH Hwang","year":"2021","unstructured":"Hwang, Y. H. et al. Can reactogenicity predict immunogenicity after COVID-19 vaccination?. Korean J. Intern. Med. 36(6), 1486\u20131491 (2021).","journal-title":"Korean J. Intern. Med."},{"key":"67945_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106860","volume":"153","author":"JE Ebinger","year":"2021","unstructured":"Ebinger, J. E. et al. Symptomology following mRNA vaccination against SARS-CoV-2. Prev. Med. 153, 106860 (2021).","journal-title":"Prev. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67945-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67945-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67945-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T09:07:36Z","timestamp":1727687256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67945-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67945"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67945-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"28 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NA, RSH, HK, and SB are members of the Orchid Pharmed medical department which is in collaboration with CinnaGen company with respect to conducting clinical trials. NP is affiliated with Vaxine Pty Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22631"}}